CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleMarket cap is $2.11B, above the global median of $1.15B
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.99TKRW2.11B · vs all stocks (USD)
Revenue (TTM)
159.06BKRW112.62M · vs all stocks (USD)
Profit Margin
-3.19%Beta
0.8820xvs all stocks
52-Week Change
108.44%vs all stocks
Market Capitalization
2.99TKRW2.11B · vs all stocks (USD)
Enterprise Value
3.04TKRW2.15B · vs all stocks (USD)
Forward P/E
511.13xPrice to Sales (TTM)
19.38xPrice to Book (MRQ)
18.55xEnterprise to Revenue
19.11xGross Margin
53.27%Profit Margin
-3.19%Operating Margin
2.10%Return on Assets (TTM)
-0.11%Return on Equity (TTM)
-3.16%Revenue (TTM)
159.06BKRW112.62M · vs all stocks (USD)
Revenue per Share (TTM)
3.15KKRWUpdated Aug 19, 2026Quarterly Revenue Growth
10.70%Gross Profit (TTM)
82.89BKRW58.69M · vs all stocks (USD)
EBITDA (TTM)
2.84BKRW2.01M · vs all stocks (USD)
Net Income (TTM)
-5.08BKRW-3.59M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
10.73%Operating Cash Flow (TTM)
-732.36MKRW-518.54K · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-7.79BKRW-5.51M · vs all stocks (USD)
Payout Ratio
0.00%Revenue
155.18BKRWFY2025 · Dec 31, 2025Cost of Goods Sold
74.33BKRWFY2025 · Dec 31, 2025Gross Profit
80.86BKRWFY2025 · Dec 31, 2025Operating Income
-915.81MKRW-648.43K · vs all stocks (USD)
Pre-tax Income
-6.18BKRWFY2025 · Dec 31, 2025Income Tax Expense
-620.72MKRWFY2025 · Dec 31, 2025Net Income
-5.56BKRWFY2025 · Dec 31, 2025EBIT
-6.04BKRWFY2025 · Dec 31, 2025EBITDA (Income Statement)
2.84BKRWFY2025 · Dec 31, 2025Research & Development
19.31BKRWFY2025 · Dec 31, 2025Selling, General & Administrative
38.27BKRWFY2025 · Dec 31, 2025Other Operating Expenses
749.97MKRWFY2025 · Dec 31, 2025Non-operating Interest Income
263.11MKRWFY2025 · Dec 31, 2025Non-operating Interest Expense
142.51MKRWFY2025 · Dec 31, 2025Net Income from Continuing Operations
-5.56BKRWFY2025 · Dec 31, 2025Operating Cash Flow
-7.11BKRWFY2025 · Dec 31, 2025Free Cash Flow
-8.03BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
24.74BKRWFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-5.56BKRWFY2025 · Dec 31, 2025Stock-based Compensation
340.68MKRWFY2025 · Dec 31, 2025Other Non-cash Items
-77.38MKRWFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
1.24BKRWFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.06BKRWFY2025 · Dec 31, 2025Capital Expenditures
-924.07MKRWFY2025 · Dec 31, 2025Net Intangibles (CF)
-13.17BKRWFY2025 · Dec 31, 2025Net Acquisitions
-3.00BKRWFY2025 · Dec 31, 2025Purchase of Investments
-2.15BKRWFY2025 · Dec 31, 2025Other Investing Activity
199.46MKRWFY2025 · Dec 31, 2025Net Investing Cash Flow
-5.87BKRWFY2025 · Dec 31, 2025Long-term Debt Issuance
15.00BKRWFY2025 · Dec 31, 2025Net Short-term Debt Issuance
15.89BKRWFY2025 · Dec 31, 2025Common Stock Repurchase
-3.22BKRWFY2025 · Dec 31, 2025Net Financing Cash Flow
30.56BKRWFY2025 · Dec 31, 2025Shares Outstanding
50.78MSharesUpdated Aug 19, 2026Float Shares
34.45MSharesUpdated Aug 19, 2026% Held by Insiders
38.22%vs all stocks
% Held by Institutions
16.46%vs all stocks
Total Cash (MRQ)
36.16BKRW25.60M · vs all stocks (USD)
Total Cash per Share (MRQ)
711.89KRWUpdated Aug 19, 2026Total Debt (MRQ)
44.20BKRW31.29M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2722xCurrent Ratio (MRQ)
1.60xBook Value per Share (MRQ)
3.20KKRWUpdated Aug 19, 2026Total Assets
225.22BKRW159.47M · vs all stocks (USD)
Total Current Assets
84.91BKRWFY2025 · Dec 31, 2025Total Liabilities
63.54BKRWFY2025 · Dec 31, 2025Total Non-current Assets
140.31BKRWFY2025 · Dec 31, 2025Total Non-current Liabilities
19.08BKRWFY2025 · Dec 31, 2025Total Current Liabilities
44.47BKRWFY2025 · Dec 31, 2025Cash Equivalents
24.74BKRWFY2025 · Dec 31, 2025Cash & Cash Equivalents
24.74BKRWFY2025 · Dec 31, 2025Accounts Receivable
16.87BKRWFY2025 · Dec 31, 2025Inventory
38.11BKRWFY2025 · Dec 31, 2025Accounts Payable
5.14BKRWFY2025 · Dec 31, 2025Short-term Debt
16.33BKRWFY2025 · Dec 31, 2025Other Current Liabilities
2.29BKRWFY2025 · Dec 31, 2025Long-term Debt
15.59BKRWFY2025 · Dec 31, 2025Other Non-current Liabilities
120.00KRWFY2025 · Dec 31, 2025Common Stock (Book)
26.12BKRWFY2025 · Dec 31, 2025Retained Earnings
21.13BKRWFY2025 · Dec 31, 2025Total Shareholders' Equity
161.68BKRW114.48M · vs all stocks (USD)
Treasury Stock
14.66BKRWFY2025 · Dec 31, 202552-Week Low
28.05KKRWUpdated Aug 19, 202652-Week High
73.00KKRWUpdated Aug 19, 202652-Week Change
108.44%vs all stocks
Beta
0.8820xvs all stocks
50-Day MA
53.55KKRWUpdated Aug 19, 2026200-Day MA
50.82KKRWUpdated Aug 19, 2026Avg 10-Day Volume
335.09KSharesUpdated Aug 19, 2026Avg 30-Day Volume
358.75KSharesUpdated Aug 19, 2026Diluted EPS (TTM)
-109.00KRWUpdated Aug 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.53Profit Margin: -0.03
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Market cap is $2.11B, above the global median of $1.15BNotable
Market cap (USD): 2,113,765,655.964Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Eris Lifesciences Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Axogen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Anhui Anke Biotechnology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
GemPharmatech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Verano Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jinyu Bio-Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Ab&B Bio-Tech Co., Ltd. (JS)
Tier 1ProductionApproval-Gated PipelineRule
Kalbe Farma Tbk. PT
Tier 1ProductionApproval-Gated PipelineRuleFlow
Shandong Weigao Blood Purification Products Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Monte Rosa Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule